• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Budicort Respules 0.5 mg / 2 ml
    / Astra Zeneca

    Active Ingredient
    Budesonide 0.5 mg

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Suspension for Inhalation

    20 x 0.5 mg / 2 ml

    partial basket chart 10489 2501


    Bronchial asthma: Administration can be once or twice daily. Once daily administration can be used for daily doses of 0.25 – 1 mg.
    Initiation of therapy: When treatment is started, during periods of severe asthma and while reducing or discontinuing oral glucocorticosteroids, the recommended dose of Budicort Respules is:
    Adults (including elderly): Usually 1 – 2 mg total daily dose. In very severe cases the dosage may be increased.
    Children 12 years and older: Dosage as for adults.
    Children 6 months to 12 years: 0.25 – 0.5 mg total daily dose. In patients depending on oral glucocorticosteroids, a higher starting dose, e.g. 1 mg total daily dose may be considered.
    Maintenance dose: The maintenance dose should be individualised and be the lowest dose which keeps the patient symptom-free.
    Dose-range maintenance dose
    Adults (including elderly and children 12 years and older): 0.5 – 4 mg total daily dose. In very severe cases the dose may be further increased.
    Children 6 months to 12 years: 0.25 – 2 mg total daily dose.
    See prescribing information for full details.


    Bronchial asthma when other therapy unsuitable or insufficient.


    Known hypersensitivity. See prescribing information for full details.

    Special Precautions

    Patients should be advised to have their rescue medicdbation available at all times. Patients transferring from oral steroids may remain at risk of impaired adrenal reserve for a considerable time. The patient should be instructed to rinse the mouth with water after each dosing occasion. Caution in patients with thyrotoxicosis, phaeochromocytoma, diabetes mellitus, untreated hypokalaemia, hypertrophic obstructive cardiomyopathy, idiopathic subvalvular aortic stenosis, severe hypertension, aneurism or other severe cardiovascular disorders, when treating patients with prolongation of the QTc-interval. Additional blood glucose controls should be considered in diabetic patients. Pregnancy and lactation. Patients with lung tuberculosis and fungal and viral infections in the airways.
    See prescribing information for full details.

    Side Effects

    Headache, palpitations, tremor, candida infections in the oropharynx, mild irritation in the throat, coughing, hoarseness. Rare cases of bronchoconstriction have been reported. Nervousness, restlessness and depression, behavioral disturbances in children. Rare cases of cataract after prolonged use of corticosteroid aerosols have been reported.
    See prescribing information for full details.

    Drug interactions

    See prescribing information for full details.

    AstraZeneca AB Gärtunavägen Sweden